结节性淋巴细胞为主型霍奇金淋巴瘤的主动监测
在纪念斯隆凯特琳癌症中心1974至2016年连续诊断的163例结节性淋巴细胞为主型霍奇金淋巴瘤患者中,23%接受主动监测;主动监测组5年无进展生存率为77%,低于接受任何积极治疗者的87%(P=0.017),但第二无进展生存率和总生存率无差异;仅27%的主动监测患者最终需要治疗,中位时间为61个月,且无人死亡。
要点
- NLPHL预后良好,5年总生存率99%,仅1/7死亡与淋巴瘤相关。
- 主动监测组5年PFS为77%,低于积极治疗组的87%(P=0.017)。
- 该PFS差异未转化为第二PFS或总生存的差异。
核心结论
- NLPHL预后极佳;在回顾性分析的局限性内,主动监测是部分NLPHL患者可行的初始管理策略。
研究设计与样本
- 回顾性分析纳入纪念斯隆凯特琳癌症中心1974至2016年诊断并随访的163例16岁及以上连续NLPHL患者。
- 治疗方式包括单纯放疗46%、主动监测23%、化疗16%、联合模式12%和利妥昔单抗单药4%。
- 中位随访69个月,比较主动监测与其他治疗策略的结局。
主要发现
- 5年无进展生存率85%(95%CI 78-90),第二无进展生存率97%(95%CI 92-99),总生存率99%(95%CI 95-100)。
- 7例死亡中仅1例与淋巴瘤相关。
- 主动监测组5年无进展生存率77%(95%CI 56-89) vs 接受任何积极治疗组87%(95%CI 79-92;P=0.017),主动监测组较短。
- 该差异未转化为第二无进展生存率或总生存率的获益。
- 主动监测患者中仅10例(27%)最终需要治疗,中位时间61个月,无人死亡。
临床怎么用
- 作者认为,在回顾性分析的局限性内,主动监测是部分NLPHL患者可行的初始管理策略。
局限性
- 原文自述为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of lymphoma that, like other Hodgkin lymphomas, has historically been treated aggressively. However, in most cases, NLPHL has an indolent course, which raises the question of to what extent these patients require aggressive upfront treatment. We describe the management and outcomes of consecutive NLPHL patients diagnosed at Memorial Sloan Kettering Cancer Center (MSK), with a focus on evaluating active surveillance. All patients aged 16 years or older diagnosed and followed at MSK between 1974 and 2016 were included. Treatment outcomes were compared between management with active surveillance and other strategies. We identified 163 consecutive patients who were treated with radiotherapy alone (46%), active surveillance (23%), chemotherapy (16%), combined modality (12%), or rituximab monotherapy (4%). Median follow-up was 69 months. Five-year progression-free survival (PFS), second PFS (PFS2), and overall survival (OS) estimates were 85% (95% confidence interval [CI], 78-90), 97% (95% CI, 92-99), and 99% (95% CI, 95-100), respectively. Only 1 of 7 deaths was lymphoma related. Patients managed with active surveillance had slightly shorter PFS than those receiving any active treatment, with 5-year PFS of 77% (95% CI, 56-89) vs 87% (95% CI, 79-92; P = .017). This difference did not translate into better PFS2 or OS. Only 10 patients managed with active surveillance (27%) eventually required treatment, after a median of 61 months, and none died. NLPHL has an excellent prognosis. Within the limitations of a retrospective analysis, active surveillance is a viable initial management strategy for selected NLPHL patients.
引用
- Borchmann S, Joffe E, Moskowitz CH, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019. PMID: 30770396. doi:10.1182/blood-2018-10-877761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。